Potential blood biomarkers for stroke

Expert Review of Proteomics

Volumn 9, Issue 4, 2012, Pages 437-449

  Laborde, Carlos M ^a   Mourino Alvarez, Laura ^a   Akerstrom, Finn ^a,b   Padial, Luis R ^a,b   Vivanco, Fernando ^c,d   Gil Dones, Felix ^a   Barderas, Maria G ^a  

^a HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c UAM)   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

hemorrhagic stroke; ischemic stroke; mass spectrometry; metabolomics; potential biomarker; proteomics

Indexed keywords

APOLIPOPROTEIN A2; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; COPEPTIN; D DIMER; DJ 1 PROTEIN; FERRITIN; FORMIC ACID; GELATINASE B; GLUTAMINE; GLYCOLIC ACID; HOMOARGININE; INTERLEUKIN 6; ISCHEMIA MODIFIED ALBUMIN; ISOPROSTANE DERIVATIVE; LACTIC ACID; METHANOL; MYELOPEROXIDASE; N(G),N(G) DIMETHYLARGININE; PEPTIDYLPROLYL ISOMERASE; PROTEIN; PROTEIN S100B; PYRUVIC ACID; SOMATOMEDIN BINDING PROTEIN 4; TAURINE; THROMBIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROTIC PLAQUE; BRAIN ARTERY ANEURYSM RUPTURE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; METABOLITE; METABOLOMICS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROTEOMICS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STROKE; SUBARACHNOID HEMORRHAGE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSIENT ISCHEMIC ATTACK;

BIOLOGICAL MARKERS; BLOOD PROTEINS; BRAIN; HUMANS; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; PROGNOSIS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STROKE; THROMBIN;

EID: 84866311507     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.12.33     Document Type: Review

References (137)

1. Thorvaldsen P, Kuulasmaa K, Rajakangas AM, Rastenyte D, Sarti C, Wilhelmsen L . Stroke trends in the WHO MONICA project. Stroke 28 (3), 500 - 506 (1997). (Pubitemid 27118368)
2. Rothwell PM, Algra A, Amarenco P . Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 377 (9778), 1681 - 1692 (2011).
3. Saka O, McGuire A, Wolfe C . Cost of stroke in the United Kingdom. Age Ageing 38 (1), 27 - 32 (2009).
4. Rothwell PM . The high cost of not funding stroke research: A comparison with heart disease and cancer. Lancet 357 (9268), 1612 - 1616 (2001). (Pubitemid 32488832)
5. Hennerici MG . The unstable plaque. Cerebrovasc. Dis. 17 (Suppl. 3), 17 - 22 (2004). (Pubitemid 38134843)
6. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ . Thrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev. 4, CD000213 (2009).
7. Mathur RK . Role of diabetes, hypertension, and cigarette smoking on atherosclerosis. J. Cardiovasc. Dis. Res. 1 (2), 64 - 68 (2010).
8. Talayero B, Sacks F . The role of triglycerides in atherosclerosis. Curr. Cardiol. Rep. 13 (6), 544 - 552 (2011).
9. Karim R, Buchanan TA, Hodis HN, Li Y, Mack WJ . The association of smoking and subclinical atherosclerosis in Type 2 diabetes: Modifi cation by duration of diabetes. Diabet. Med. 22 (1), 81 - 87 (2005). (Pubitemid 40188291)
10. Easton JD, Saver JL, Albers GW et al .; American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease . Defi nition and evaluation of transient ischemic attack: A scientifi c statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affi rms the value of this statement as an educational tool for neurologists. Stroke 40 (6), 2276 - 2293 (2009).
11. Kleindorfer D, Panagos P, Pancioli A et al . Incidence and short-term prognosis of transient ischemic attack in a populationbased study. Stroke 36 (4), 720 - 723 (2005).
12. Coull AJ, Lovett JK, Rothwell PM; Oxford Vascular Study . Population-based study of early risk of stroke after transient ischaemic attack or minor stroke: Implications for public education and organisation of services. BMJ 328 (7435), 326 (2004).
13. Daffertshofer M, Mielke O, Pullwitt A, Felsenstein M, Hennerici M . Transient ischemic attacks are more than 'ministrokes'. Stroke 35 (11), 2453 - 2458 (2004). (Pubitemid 39458398)
14. Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopfl ocher DP . The high risk of stroke immediately after transient ischemic attack: A populationbased study. Neurology 62 (11), 2015 - 2020 (2004).
15. Konstas AA, Wintermark M, Lev MH . CT perfusion imaging in acute stroke. Neuroimaging Clin. N. Am. 21 (2) , 215 - 238, ix (2011).
16. Fung SH, Roccatagliata L, Gonzalez RG, Schaefer PW . MR diffusion imaging in stroke. Neuroimaging Clin. N. Am. 21 (2) , 345 - 377, xi (2011).
17. Grotta JC, Chiu D, Lu M et al . Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 30 (8), 1528 - 1533 (1999). (Pubitemid 29379597)
18. Manolio T . Novel risk markers and clinical practice. N. Engl. J. Med. 349 (17), 1587 - 1589 (2003). (Pubitemid 37288564)
19. Arab S, Gramolini AO, Ping P et al . Cardiovascular proteomics: Tools to develop novel biomarkers and potential applications. J. Am. Coll. Cardiol. 48 (9), 1733 - 1741 (2006). (Pubitemid 44648616)
20. Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC. A potential cerebrospinal fl uid and plasmatic marker for the diagnosis of Creutzfeldt- Jakob disease. Proteomics 3 (8), 1495 - 1499 (2003). (Pubitemid 37048075)
21. Bonifati V, Rizzu P, van Baren MJ et al . Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (5604), 256 - 259 (2003). (Pubitemid 36131051)
22. Wilson MA, Collins JL, Hod Y, Ringe D, Petsko GA . The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early-onset Parkinson's disease. Proc. Natl Acad. Sci. USA 100 (16), 9256 - 9261 (2003). (Pubitemid 37033916)
23. Kim SH, Fountoulakis M, Cairns NJ, Lubec G . Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochem. Biophys. Res. Commun. 296 (4), 970 - 975 (2002).
24. Allard L, Burkhard PR, Lescuyer P et al . PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin. Chem. 51 (11), 2043 - 2051 (2005). (Pubitemid 41532619)
25. Allard L, Turck N, Burkhard PR et al . Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke. Biomark. Insights 2, 155 - 164 (2007).
26. Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K . Serum and urinary human heart fatty acidbinding protein in acute myocardial infarction. Clin. Biochem. 24 (2), 195 - 201 (1991).
27. Watanabe K, Wakabayashi H, Veerkamp JH, Ono T, Suzuki T . Immunohistochemical distribution of heart-type fatty acid-binding protein immunoreactivity in normal human tissues and in acute myocardial infarct. J. Pathol. 170 (1), 59 - 65 (1993). (Pubitemid 23130585)
28. Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ . Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol. Cell. Biochem. 116 (1-2), 155 - 162 (1992).
29. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC . Fatty acid binding protein as a serum marker for the early diagnosis of stroke: A pilot study. Mol. Cell Proteomics 3 (1), 66 - 72 (2004). (Pubitemid 38697105)
30. Sbarouni E, Georgiadou P, Voudris V . Ischemia-modifi ed albumin changes - review and clinical implications. Clin. Chem. Lab. Med. 49 (2), 177 - 184 (2011).
31. Abboud H, Labreuche J, Meseguer E et al . Ischemia-modifi ed albumin in acute stroke. Cerebrovasc. Dis. 23 (2-3), 216 - 220 (2007).
32. Gunduz A, Turedi S, Mentese A et al . Ischemia-modifi ed albumin levels in cerebrovascular accidents. Am. J. Emerg. Med. 26 (8), 874 - 878 (2008).
33. Van Lint P, Libert C . Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and infl ammation. J. Leukoc. Biol. 82 (6), 1375 - 1381 (2007). (Pubitemid 350276947)
34. Gidday JM, Gasche YG, Copin JC et al . Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinfl ammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol. 289 (2), H558 - H568 (2005). (Pubitemid 41129369)
35. Ramos-Fernandez M, Bellolio MF, Stead LG . Matrix metalloproteinase-9 as a marker for acute ischemic stroke: A systematic review. J. Stroke Cerebrovasc. Dis. 20 (1), 47 - 54 (2011).
36. Montaner J, Alvarez-Sabín J, Molina C et al . Matrix metalloproteinase expression after human cardioembolic stroke: Temporal profi le and relation to neurological impairment. Stroke 32 (8), 1759 - 1766 (2001). (Pubitemid 32772204)
37. Brouns R, Wauters A, De Surgeloose D, Mariën P, De Deyn PP . Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome. Eur. Neurol. 65 (1), 23 - 31 (2011).
38. Rosell A, Alvarez-Sabín J, Arenillas JF et al . A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusionweighted image lesion increase in human stroke. Stroke 36 (7), 1415 - 1420 (2005). (Pubitemid 40967504)
39. Sotgiu S, Zanda B, Marchetti B et al . Infl ammatory biomarkers in blood of patients with acute brain ischemia. Eur. J. Neurol. 13 (5), 505 - 513 (2006). (Pubitemid 43823367)
40. Vukasovic I, Tesija-Kuna A, Topic E, Supanc V, Demarin V, Petrovcic M . Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Clin. Chem. Lab. Med. 44 (4), 428 - 434 (2006).
41. Al-Tamimi M, Gardiner EE, Thom JY et al . Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke 42 (2), 498 - 500 (2011).
42. Carcaillon L, Alhenc-Gelas M, Bejot Y et al . Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: The Three-City cohort study. Arterioscler. Thromb. Vasc. Biol. 31 (6), 1445 - 1451 (2011).
43. Kim MH, Kang SY, Kim MC, Lee WI . Plasma biomarkers in the diagnosis of acute ischemic stroke. Ann. Clin. Lab. Sci. 40 (4), 336 - 341 (2010) .
44. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC; BRAIN Study Group . Clinical usefulness of a biomarkerbased diagnostic test for acute stroke: The Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 40 (1), 77 - 85 (2009).
45. Gil-Dones F, Martin-Rojas T, Lopez-Almodovar LF et al . Valvular aortic stenosis: A proteomic insight. Clin. Med. Insights. Cardiol. 4, 1 - 7 (2010).
46. de la Cuesta F, Barderas MG, Calvo E et al . Secretome analysis of atherosclerotic and non-atherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. J. Proteomics 75 (10), 2960 - 2971 (2011).
47. de la Cuesta F, Alvarez-Llamas G, Maroto AS et al . A proteomic focus on the alterations occurring at the human atherosclerotic coronary intima. Mol. Cell. Proteomics 10 (4), 13 (2011).
48. Terao Y, Takada M, Tanabe T, Ando Y, Fukusaki M, Sumikawa K . Microalbuminuria is a prognostic predictor in aneurysmal subarachnoid hemorrhage. I ntensive Care Med. 33 (6), 1000 - 1006 (2007). (Pubitemid 46835410)
49. Petzold A, Michel P, Stock M, Schluep M . Glial and axonal body fl uid biomarkers are related to infarct volume, severity, and outcome. J. Stroke Cerebrovasc. Dis. 17 (4), 196 - 203 (2008). (Pubitemid 351853439)
50. Beridze M, Sanikidze T, Shakarishvili R, Intskirveli N, Bornstein NM . Selected acute phase CSF factors in ischemic stroke: Fi ndings and prognostic value. BMC Neurol. 11, 41 (2011).
51. Stastna M, Van Eyk JE . Secreted proteins as a fundamental source for biomarker discovery. Proteomics 12 (4-5), 722 - 735 (2012).
52. Zeng G-Q, Zhang P-F, Deng X-M et al . Identifi cation of novel biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics. Mol. Cell. Proteomics 11(6), M111.013946 (2012).
53. Chen CY, Chi LM, Chi HC et al . Stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics study of a thyroid hormoneregulated secretome in human hepatoma cells. Mol. Cell Proteomics 11 (4) , M111.011270 (2012).
54. Zhang X, Guo T, Wang H et al . Potential biomarkers of acute cerebral infarction detected by SELDI-TOF-MS. Am. J. Clin. Pathol. 130 (2), 299 - 304 (2008) .
55. Prentice RL, Paczesny S, Aragaki A et al . Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identifi ed by in-depth plasma proteome profi ling. Genome Med. 2 (7), 48 (2010) .
56. Saminathan R, Bai J, Sadrolodabaee L et al . VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: Transthyretin precursor as a potential biomarker. PLoS ONE 5 (12), e15064 (2010).
57. Ning M, Sarracino DA, Kho AT et al . Proteomic temporal profi le of human brain endothelium after oxidative stress. Stroke 42 (1), 37 - 43 (2011) .
58. Ning M, Sarracino DA, Buonanno FS et al . Proteomic protease substrate profi ling of tPA treatment in acute ischemic stroke patients: A step toward individualizing thrombolytic therapy at the bedside. Transl. Stroke Res. 1 (4), 268 - 275 (2010).
59. Lau D, Baldus S . Myeloperoxidase and its contributory role in infl ammatory vascular disease. Pharmacol. Ther. 111 (1), 16 - 26 (2006). (Pubitemid 43765542)
60. Baldus S, Heeschen C, Meinertz T et al .; CAPTURE Investigators . Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (12), 1440 - 1445 (2003). (Pubitemid 37176448)
61. Cojocaru IM, Cojocaru M, Iliescu I et al . Plasma myeloperoxidase levels in patients with acute ischemic stroke. Rom. J. Intern. Med. 48 (1), 101 - 104 (2010).
62. Katan M, Fluri F, Schuetz P et al . Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J. Am. Coll. Cardiol. 56 (13), 1045 - 1053 (2010).
63. Luo Y, Wang Z, Li J, Xu Y . Serum CRP concentrations and severity of ischemic stroke subtypes. Can. J. Neurol. Sci. 39 (1), 69 - 73 (2012).
64. Eikelboom JW, Hankey GJ, Baker RI et al . C-reactive protein in ischemic stroke and its etiologic subtypes. J. Stroke Cerebrovasc. Dis. 12 (2), 74 - 81 (2003). (Pubitemid 36506246)
65. Wagner KR, Sharp FR, Ardizzone TD, Lu A, Clark JF . Heme and iron metabolism: Role in cerebral hemorrhage. J. Cereb. Blood Flow Metab. 23 (6), 629 - 652 (2003). (Pubitemid 36713668)
66. Perez de la Ossa N, Sobrino T, Silva Y et al . Iron-related brain damage in patients with intracerebral hemorrhage. Stroke 41 (4), 810 - 813 (2010).
67. Kelly D, Squire IB, Khan SQ et al . C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J. Card. Fail. 14 (9), 739 - 745 (2008).
68. Khan SQ, Dhillon OS, O'Brien RJ et al . C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115 (16), 2103 - 2110 (2007). (Pubitemid 46659061)
69. Alehagen U, Dahlström U, Rehfeld JF, Goetze JP . Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 305 (20), 2088 - 2095 (2011).
70. Zweifel C, Katan M, Schuetz P et al . Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol. 10, 34 (2010).
71. Dong XQ, Huang M, Yu WH et al . Change in plasma copeptin level after acute spontaneous basal ganglia hemorrhage. Peptides 32 (2), 253 - 257 (2011).
72. Kapural M, Krizanac-Bengez LJ, Barnett G et al . Serum S-100 as a possible marker of blood-brain barrier disruption. Brain Res. 940 (1-2), 102 - 104 (2002). (Pubitemid 34521759)
73. Stranjalis G, Korfi as S, Psachoulia C, Kouyialis A, Sakas DE, Mendelow AD . The prognostic value of serum S-100B protein in spontaneous subarachnoid haemorrhage. Acta Neurochir. (Wien) 149 (3), 231 - 237; discussion 237 (2007). (Pubitemid 46365433)
74. Sanchez-Peña P, Pereira AR, Sourour NA et al . S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage. Crit. Care Med. 36 (8), 2267 - 2273 (2008).
75. Khatri P, Wechsler LR, Broderick JP . Intracranial hemorrhage associated with revascularization therapies. Stroke 38 (2), 431 - 440 (2007). (Pubitemid 46188260)
76. Foerch C, Wunderlich MT, Dvorak F et al . Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 38 (9), 2491 - 2495 (2007). (Pubitemid 47329627)
77. Kaneko T, Kasaoka S, Miyauchi T et al . Serum glial fi brillary acidic protein as a predictive biomarker of neurological outcome after cardiac arrest. Resuscitation 80 (7), 790 - 794 (2009).
78. Pelinka LE, Kroepfl A, Schmidhammer R et al . Glial fi brillary acidic protein in serum after traumatic brain injury and multiple trauma. J. Trauma 57 (5), 1006 - 1012 (2004). (Pubitemid 39579285)
79. Nylén K, Ost M, Csajbok LZ et al . Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J. Neurol. Sci. 240 (1-2), 85 - 91 (2006). (Pubitemid 41814959)
80. Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B . An acidic protein isolated from fi brous astrocytes. Brain Res. 28 (2), 351 - 354 (1971).
81. Nylén K, Csajbok LZ, Ost M et al . Serum glial fi brillary acidic protein is related to focal brain injury and outcome after aneurysmal subarachnoid hemorrhage. Stroke 38 (5), 1489 - 1494 (2007). (Pubitemid 46684150)
82. Jung JY, Lee HS, Kang DG et al . 1 H-NMR-based metabolomics study of cerebral infarction. Stroke 42 (5), 1282 - 1288 (2011) .
83. Kelly PJ, Morrow JD, Ning M et al . Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 39 (1), 100 - 104 (2008).
84. Omenn GS, States DJ, Adamski M et al . Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5 (13), 3226 - 3245 (2005). (Pubitemid 41192032)
85. Mamatha SN, Nagaraja D, Philip M, Christopher R . Asymmetric dimethylarginine as a risk marker for early-onset ischemic stroke in Indian population. Clin. Chim. Acta 412 (1-2), 139 - 142 (2011).
86. Ghandforoush-Sattari M, Mashayekhi SO, Nemati M, Ayromlou H . Changes in plasma concentration of taurine in stroke. Neurosci. Lett. 496 (3), 172 - 175 (2011).
87. Krzywkowski P, Sebastiani G, Williams S, Delorme D, Greenberg B . Tramiprosate prevents amyloid β-induced inhibition of long-term potentiation in rat hippocampal slices. Presented at : 8th International Conference AD/PD . Salzburg, Austria, 14-18 March (2007).
88. Azzi M, Morissette C, Fallon L . Involvement of both GABA-dependent and -independent pathways in tramiprosate neuroprotective effects against amyloid-β toxicity. Presented at : 8th International Conference AD/PD . Salzburg, Austria, 14-18 March (2007).
89. Cataldo MC, Calcara ML, Caputo G, Mammina C . Association of total serum cholesterol with functional outcome following home care rehabilitation in Italian patients with stroke. Disabil. Health J. 5 (2), 111 - 116 (2012).
90. Zuliani G, Cherubini A, Atti AR et al . Low cholesterol levels are associated with short-term mortality in older patients with ischemic stroke. J. Gerontol. A Biol. Sci. Med. Sci. 59 (3), 293 - 297 (2004). (Pubitemid 38375345)
91. Olsen TS, Christensen RH, Kammersgaard LP, Andersen KK . Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality: Ten-year follow-up of ischemic strokes in the Copenhagen Stroke Study. Stroke 38 (10), 2646 - 2651 (2007). (Pubitemid 47493998)
92. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG . Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300 (18), 2142 - 2152 (2008).
93. Bonaventure A, Kurth T, Pico F et al . Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis 210 (1), 243 - 248 (2010).
94. Kakoki M, Kim HS, Edgell CJ, Maeda N, Smithies O, Mattson DL . Amino acids as modulators of endothelium-derived nitric oxide. Am. J. Physiol. Renal Physiol. 291 (2), F297 - F304 (2006). (Pubitemid 44148119)
95. Pilz S, Tomaschitz A, Meinitzer A et al . Low serum homoarginine is a novel risk factor for fatal strokes in patients undergoing coronary angiography. Stroke 42 (4), 1132 - 1134 (2011).
96. Ungerstedt U . Microdialysis - principles and applications for studies in animals and man. J. Intern. Med. 230 (4), 365 - 373 (1991).
97. Vespa P, Bergsneider M, Hattori N et al . Metabolic crisis without brain ischemia is common after traumatic brain injury: A combined microdialysis and positron emission tomography study. J. Cereb. Blood Flow Metab. 25 (6), 763 - 774 (2005). (Pubitemid 40705611)
98. Schmidt JM, Ko SB, Helbok R et al . Cerebral perfusion pressure thresholds for brain tissue hypoxia and metabolic crisis after poor-grade subarachnoid hemorrhage. Stroke 42 (5), 1351 - 1356 (2011).
99. Chen HI, Stiefel MF, Oddo M et al . Detection of cerebral compromise with multimodality monitoring in patients with subarachnoid hemorrhage. Neurosurgery 69 (1), 53 - 63; discussion 63 (2011).
100. Oddo M, Villa F, Citerio G . Brain multimodality monitoring: An update. Curr. Opin. Crit. Care 18 (2), 111 - 118 (2012).
101. Sarrafzadeh A, Haux D, Küchler I, Lanksch WR, Unterberg AW . Poor-grade aneurysmal subarachnoid hemorrhage: Relationship of cerebral metabolism to outcome. J. Neurosurg. 100 (3), 400 - 406 (2004) . (Pubitemid 38269066)
102. Sarrafzadeh A, Haux D, Sakowitz O et al . Acute focal neurological defi cits in aneurysmal subarachnoid hemorrhage: Relation of clinical course, CT fi ndings, and metabolite abnormalities monitored with bedside microdialysis. Stroke 34 (6), 1382 - 1388 (2003). (Pubitemid 36693502)
103. Zetterling M, Hillered L, Samuelsson C, Karlsson T, Enblad P, Ronne-Engström E . Temporal patterns of interstitial pyruvate and amino acids after subarachnoid haemorrhage are related to the level of consciousness - a clinical microdialysis study. Acta Neurochir. (Wien) 151 (7), 771 - 780; discussion 780 (2009).
104. Ruchoux MM, Brulin P, Brillault J, Dehouck MP, Cecchelli R, Bataillard M . Lessons from CADASIL. Ann. NY Acad. Sci. 977, 224 - 231 (2002). (Pubitemid 35418157)
105. Natowicz M, Kelley RI . Mendelian etiologies of stroke. Ann. Neurol. 22 (2), 175 - 192 (1987). (Pubitemid 17131151)
106. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP . Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med. 332 (14), 912 - 917 (1995).
107. Longstreth WT Jr, Rosendaal FR, Siscovick DS et al . Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A) . Stroke 29 (3), 577 - 580 (1998). (Pubitemid 28145781)
108. Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C . Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fi brinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 28 (7), 1392 - 1395 (1997). (Pubitemid 27300676)
109. Lovat F, Valeri N, Croce CM . MicroRNAs in the pathogenesis of cancer. Semin. Oncol. 38 (6), 724 - 733 (2011).
110. Thum T . MicroRNA therapeutics in cardiovascular medicine. EMBO Mol. Med. 4 (1), 3 - 14 (2012).
111. Sharp FR, Jickling GC, Stamova B et al . Molecular markers and mechanisms of stroke: RNA studies of blood in animals and humans. J. Cereb. Blood Flow Metab. 31 (7), 1513 - 1531 (2011).
112. Jickling GC, Stamova B, Ander BP et al . Profi les of lacunar and nonlacunar stroke. Ann. Neurol. 70 (3), 477 - 485 (2011).
113. Zhan X, Jickling GC, Tian Y et al . Transient ischemic attacks characterized by RNA profi les in blood. Neurology 77 (19), 1718 - 1724 (2011).
114. Rink C, Khanna S . MicroRNA in ischemic stroke etiology and pathology. Physiol. Genomics 43 (10), 521 - 528 (2011).
115. György B, Tóth E, Tarcsa E, Falus A, Buzás EI . Citrullination: A posttranslational modifi cation in health and disease. Int. J. Biochem. Cell Biol. 38 (10), 1662 - 1677 (2006). (Pubitemid 43947646)
116. Baenziger JU. A major step on the road to understanding a unique posttranslational modifi cation and its role in a genetic disease. Cell 113 (4), 421 - 422 (2003). (Pubitemid 36588743)
117. Bierhaus A, Nawroth PP . Posttranslational modifi cation of lipoproteins - a fatal attraction in metabolic disease? J. Alzheimers Dis. 7 (4), 315 - 317 (2005).
118. Lixia M, Zhijian C, Chao S, Chaojiang G, Congyi Z . Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line. J. Biochem. Mol. Biol. 40 (1), 15 - 21 (2007). (Pubitemid 46182730)
119. Zhou A, Zhang F, Chen JY . PEPPI: A peptidomic database of human protein isoforms for proteomics experiments. BMC Bioinformatics 11 (Suppl. 6), S7 (2010).
120. Beer LA, Tang HY, Barnhart KT, Speicher DW . Plasma biomarker discovery using 3D protein profi ling coupled with label-free quantitation. Methods Mol. Biol. 728, 3 - 27 (2011).
121. Merico D, Gfeller D, Bader GD . How to visually interpret biological data using networks. Nat. Biotechnol. 27 (10), 921 - 924 (2009).
122. Shannon P, Markiel A, Ozier O et al . Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (11), 2498 - 2504 (2003). (Pubitemid 37428274)
123. Cline MS, Smoot M, Cerami E et al . Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2 (10), 2366 - 2382 (2007).
124. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T . Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27 (3), 431 - 432 (2011).
125. Burré J, Beckhaus T, Corvey C, Karas M, Zimmermann H, Volknandt W . Synaptic vesicle proteins under conditions of rest and activation: Analysis by 2D difference gel electrophoresis. Electrophoresis 27 (17), 3488 - 3496 (2006). (Pubitemid 44430730)
126. Gillardon F, Rist W, Kussmaul L et al . Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics 7 (4), 605 - 616 (2007). (Pubitemid 46362624)
127. Swatton JE, Prabakaran S, Karp NA, Lilley KS, Bahn S . Protein profi ling of human postmortem brain using 2-dimensional fl uorescence difference gel electrophoresis (2D DIGE). Mol. Psychiatry 9 (2), 128 - 143 (2004). (Pubitemid 38299526)
128. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S . 2D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J. Proteome Res. 6 (1), 141 - 149 (2007). (Pubitemid 46173666)
129. Kultima K, Scholz B, Alm H et al . Normalization and expression changes in predefi ned sets of proteins using 2D gel electrophoresis: A proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. BMC Bioinformatics 7, 475 (2006).
130. Chen R, Vendrell I, Chen CP et al . Proteomic analysis of rat plasma following transient focal cerebral ischemia. Biomark. Med. 5 (6), 837 - 846 (2011).
131. Bergerat A, Decano J, Wu CJ et al . Prestroke proteomic changes in cerebral microvessels in stroke-prone, transgenic [hCETP]-hyperlipidemic, Dahl saltsensitive hypertensive rats. Mol. Med. 17 (7-8), 588 - 598 (2011).
132. Koh PO . Proteomic analysis of focal cerebral ischemic injury in male rats. J. Vet. Med. Sci. 72 (2), 181 - 185 (2010).
133. Lawrie AS, Hills J, Longair I et al . The clinical signifi cance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients. Thromb. Res. 130 (1), 110 - 114 (2012).
134. Rizos T, Herweh C, Jenetzky E et al . Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke 40 (11), 3547 - 3551 (2009).
135. Drescher MJ, Spence A, Rockwell D, Staff I, Smally AJ . Point-of-care testing for coagulation studies in a stroke protocol: A time-saving innovation. Am. J. Emerg. Med. 29 (1), 82 - 85 (2011).
136. Celenza A, Skinner K . Comparison of emergency department point-of-care international normalised ratio (INR) testing with laboratory-based testing. Emerg. Med. J. 28 (2), 136 - 140 (2011).
137. Alvarez-Llamas G, de la Cuesta F, Barderas ME, Darde V, Padial LR, Vivanco F . Recent advances in atherosclerosis-based proteomics: New biomarkers and a future perspective . Expert Rev. roteomics 5 (5) , 679 - 691 (2008) .